Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PS-341 in Treating Women With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00025584
First received: October 11, 2001
Last updated: January 22, 2013
Last verified: January 2013

October 11, 2001
January 22, 2013
August 2001
August 2004   (final data collection date for primary outcome measure)
Objective tumor response (CR + PR) [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
The agent would be of definite interest for further investigation if the associated response rate is at least 30% (p1), and would not be of further interest if the response rate is below 10% (p0).
Not Provided
Complete list of historical versions of study NCT00025584 on ClinicalTrials.gov Archive Site
  • Time to progression [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    Will be reported using the Kaplan-Meier method with 95% confidence intervals indicated.
  • Overall survival [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    Will be reported using the Kaplan-Meier method with 95% confidence intervals indicated.
  • Correlation between variations in the serum levels of adhesion molecules and angiogenic factors [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
    Will be evaluated and descriptive analysis will be performed.
  • Tissue markers of biological activity [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
    Will be described in case of lesions amenable to tissue biopsy. The plasma pharmacodynamics of PS-341 as measured by the 20S-proteosome assay, will be used to measured the biological activity of the drug and correlated with response to treatment and variations in biomarkers.
Not Provided
Not Provided
Not Provided
 
PS-341 in Treating Women With Metastatic Breast Cancer
Phase II Trial Of PS-341 In Metastatic Breast Cancer

PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer

PRIMARY OBJECTIVES:

I. Determine the efficacy of PS-341, in terms of response rate, in women with metastatic breast cancer.

SECONDARY OBJECTIVES:

I. Determine the clinical activity of this drug, in terms of progression-free survival, in these women.

II. Determine the toxicity profile and tolerability of this drug in these women.

III. Determine the pharmacodynamics of this drug in these women.

OUTLINE:

Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A maximum of 12-35 patients will be accrued for this study within 9-12 months.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer
  • Drug: bortezomib
    Given IV
    Other Names:
    • LDP 341
    • MLN341
    • VELCADE
  • Other: laboratory biomarker analysis
    Correlative studies
Experimental: Treatment (bortezomib)
Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Interventions:
  • Drug: bortezomib
  • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
Not Provided
August 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed invasive breast cancer

    • Clinical and/or radiological evidence of stage IV disease
  • Relapsed or resistant disease within 6-12 months after completion of prior chemotherapy with doxorubicin or epirubicin and/or paclitaxel or docetaxel foradvanced disease or in the adjuvant setting
  • At least 1 unidimensionally measurable lesion

    • At least 20 mm by conventional techniques
    • At least 10 mm by spiral CT scan
    • No bone metastases as only measurable site
    • Pleural or peritoneal effusions not acceptable as measurable disease
  • No known brain metastases
  • Hormone receptor status:

    • Estrogen receptor-negative
    • Estrogen receptor-positive
  • Female
  • Performance status - ECOG 0-2
  • Performance status - Karnofsky 60-100%
  • More than 12 weeks
  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Bilirubin normal
  • AST or ALT no greater than 2.5 times upper limit of normal
  • Creatinine normal
  • Creatinine clearance at least 60 mL/min
  • No acute ischemia or significant conduction abnormality by EKG
  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • LVEF greater than 50%
  • No uncontrolled concurrent illness
  • No psychiatric illness or social situation that would preclude study
  • No ongoing or active infection
  • No prior allergic reaction(s) to compounds of similar chemical or biologic composition to PS-341
  • No other malignancy within the past 5 years except carcinoma in situ of the cervix or basal cell skin cancer
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier-method contraception
  • See Chemotherapy
  • See Disease Characteristics
  • No more than 1 prior chemotherapy regimen for metastatic disease

    • High-dose regimen or bone marrow transplantation considered 1 prior regimen
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
  • Prior hormonal therapy for metastatic disease or in adjuvant setting allowed
  • Prior localized radiotherapy allowed if it does not influence the signal evaluable lesion
  • At least 4 weeks since prior radiotherapy and recovered
  • At least 2 weeks since prior minor surgery and recovered
  • At least 4 weeks since prior major surgery and recovered
  • No other concurrent investigational agent
  • No other concurrent investigational or commercial agents or therapies to treat this malignancy
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00025584
NCI-2012-02422, ID00-308, N01CM17003, CDR0000068976
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Massimo Cristofanilli M.D. Anderson Cancer Center
National Cancer Institute (NCI)
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP